An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Tocilizumab (Primary)
- Indications Giant cell arteritis
- Focus Adverse reactions
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.
- 28 Jul 2017 Planned initiation date changed from 7 Jul 2017 to 2 Aug 2017.